GHSI - Guardion Health Sciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4100
+0.0400 (+2.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.3700
Open1.4400
Bid0.9400 x 1100
Ask1.4400 x 900
Day's Range1.3504 - 1.4400
52 Week Range1.2800 - 4.0000
Volume7,099
Avg. Volume56,605
Market Cap31.713M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire16 days ago

    Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’

    In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial dysfunction in patients with glaucoma. San Diego, CA, June 04, 2019 (GLOBE NEWSWIRE) --  Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the launch of the Company’s second ocular health formula.

  • GlobeNewswirelast month

    Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2

    The AREDS 2 Group showed no statistical change. San Diego, CA, May 09, 2019 (GLOBE NEWSWIRE) --  Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the results of a study from research scientists at the Western University College of Optometry to clinically evaluate the visual benefits of the Company’s micronized liquid formula Lumega-Z as compared to the AREDS 2 softgel supplement in individuals with retinal drusen and at risk of developing Age-Related Macular Degeneration (AMD).

  • GlobeNewswirelast month

    Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the results of a study from research scientists at the University of Texas, San Antonio (USTA), Texas, on the effects of the Company’s Lumega-Z medical food on pericentral FDT (i.e.

  • GlobeNewswire2 months ago

    Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced that it was recently notified by the State Intellectual Property Office of the People’s Republic of China (“China”) that it has been granted trademark registrations in China for its proprietary medical food, Lumega-Z (Registration No. 27151643), and for its proprietary medical device, the MapcatSF (Registration No. 27151644). The trademark registration for Lumega-Z is effective from November 7, 2018 to November 6, 2028, and the trademark registration for the MapcatSF is effective from October 28, 2018 to October 27, 2028.

  • GlobeNewswire2 months ago

    Results of Lumega-Z Data to be Presented at ARVO

    Guardion Health Sciences, Inc.’s (the “Company”) Scientific Advisory Board member, Dr. William Sponsel will be presenting an abstract at the Association for Research in Vision and Ophthalmology (“ARVO”) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The study assessed the potential utility of the Company’s medical food product, Lumega-Z, which is designed to restore the macular protective pigment layer. The abstract concludes that in patients who had ordered 12 consecutive month’s supply of Lumega-Z, Lumega-Z treatment was associated with significant improvement in visual field function among patients with severe glaucoma who had previously shown degeneration despite having had excellent intraocular pressure control.

  • WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services
    PR Newswire2 months ago

    WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services

    JERSEY CITY, N.J. , April 11, 2019 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the closing of the initial public offering ...

  • GlobeNewswire2 months ago

    Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering

    Guardion Health Sciences Inc. (“Guardion”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced that it closed its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion. In addition, Guardion has granted the underwriters a 45-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

  • Business Wire2 months ago

    Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering

    Guardion Health Sciences Inc. (“Guardion”) (Nasdaq:GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion. In addition, Guardion has granted the underwriters a 45-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.